483 Response Drafter

Built from FDA Draft Guidance March 2026 (Docket FDA-2025-D-1504). The draft guidance is the first document FDA has published consolidating its 483 response content requirements. Every section of this draft follows those requirements.

Site name *

FDA Establishment Identifier (FEI)

Product type *

CFR section cited

483 observation text *

0 / 800 characters

What do you believe the root cause is? (optional)

0 / 400 characters

Immediate actions already taken (optional)

0 / 300 characters

Products potentially affected

0 / 300 characters

Executive signatory name and title

Target CAPA completion timeframe

Takes about 15 seconds. All fields marked * are required.

Draft 483 Response

⏰

15-business-day deadline. FDA will not delay regulatory action to review a late response. Submit within 15 business days of receiving the Form 483.

This draft is a starting framework based on the March 2026 FDA draft guidance. All placeholders marked in amber must be completed with your site-specific data before submission. Review with qualified regulatory counsel before submitting to FDA.

Full course: Responding to FDA Form 483 Observations

Covers the complete March 2026 draft guidance, root cause bias requirements, CAPA effectiveness checks and the five most common response failures that generate warning letters.

FDA Form 483 Response Drafter

Drafting your response

Draft 483 Response

Full course: Responding to FDA Form 483 Observations